Lyell Immunopharma (LYEL) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Which has preferable valuation & earnings, ABUS or LYEL?

Arbutus Biopharma has higher revenue and earnings than Lyell Immunopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$6.17M	111.54	-$69.92M	-$0.29	-12.38
Lyell Immunopharma	$60K	3,444.99	-$342.99M	-$24.29	-0.44

Do institutionals and insiders hold more shares of ABUS or LYEL?

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer ABUS or LYEL?

Arbutus Biopharma currently has a consensus target price of $5.50, suggesting a potential upside of 53.20%. Lyell Immunopharma has a consensus target price of $15.00, suggesting a potential upside of 39.41%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Arbutus Biopharma is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Which has more risk & volatility, ABUS or LYEL?

Arbutus Biopharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Does the media refer more to ABUS or LYEL?

In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 1 articles in the media. Lyell Immunopharma's average media sentiment score of 1.36 beat Arbutus Biopharma's score of 1.23 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ABUS or LYEL more profitable?

Arbutus Biopharma has a net margin of -352.24% compared to Lyell Immunopharma's net margin of -552,328.31%. Arbutus Biopharma's return on equity of -59.28% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-352.24%	-59.28%	-44.11%
Lyell Immunopharma	-552,328.31%	-85.58%	-68.85%

Summary

Arbutus Biopharma beats Lyell Immunopharma on 10 of the 15 factors compared between the two stocks.